- Daewoong Pharmaceutical and HanAll Biopharma invest in the broad potential of Turn Biotechnologies
- Turn has developed a novel cell rejuvenating platform with significant potential for application in an array of age-related diseases
Daewoong Pharmaceutical and HanAll Biopharma today announced expansion of their open collaboration strategy by investing in Turn Biotechnologies, a Silicon Valley based company focused on developing novel mRNA medicines. The companies are supporting Turn Bio’s continued development of a high-potential platform and are considering future long-term collaborations.
Turn Bio is a pre-clinical-stage biopharmaceutical company focused on cellular repair via epigenetic reprogramming of cells. The technological foundation for Turn Bio’s proprietary Epigenetic Reprogramming of Age (ERA™) methodology was developed by Turn Bio’s co-founders in the Sebastiano Lab, Institute for Stem Cell Biology and Regenerative Medicine, Stanford School of Medicine. The technology has since been patented and Turn Bio is currently using it to complete pre-clinical research on therapies targeting indications in dermatology and immunology, as well as developing therapies for ophthalmology, osteoarthritis and the muscular system.
“Many age-related diseases have long been significant areas of patients’ unmet need”, “Turn Bio’s innovative platform may bring a pivotal transformation to a wide array of therapeutic areas. HanAll is committing support and investment to help realize the full potential of this pioneering technology as Turn Bio advances to a new phase of growth.”
Dr. Almira Chabi, chief medical officer & chief development officer at HanAll Pharmaceutical International.
“The support of Daewoong Pharmaceutical and HanAll Biopharma validates our approach to cellular rejuvenation and enables Turn to expand its efforts in multiple therapeutic indications”, “We are thrilled that a company as well known for its innovation, has taken interest in our promise to transform the way medicine treats diseases of aging and we look forward to further collaborations to help change quality of life and healthcare economics globally.”
Anja Krammer, CEO at Turn Biotechnologies
The proceeds from this round of financing will support Turn Bio’s advancement towards a phase 1 trial of its mRNA therapy candidate TRN-001, which targets indications in dermatology.
